Stable angina pectoris
Conditions
Interventions
Aspirin group:Oral aspirin 100mg/d for 6 months
Clopidogrel group:Oral Clopidogrel for 75mg/d for 6 months
Ticagrelor group:Oral Ticagrelor for 90mg bid for 6 months
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, male or female; 2. Patients with stable coronary heart disease who need to be treated with anti-platelet aggregation drugs alone; 3. Those who meet the above conditions and agree to join the experiment.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women; 2. Patients taking thrombolytic drugs and anticoagulant drugs; 3. Patients with bleeding tendency or inability to receive antiplatelet drug therapy; 4. With a History of allergy to antiplatelet aggregation drugs; 5. Patients with left ventricular ejection fraction 6.0%, the patients with severe renal insufficiency (MDRD formula Gault or Cockcroft: GFR < 30 ml/min) or severe liver function damage (AST and ALT 3 times higher than normal ceiling), severe peripheral vascular disease (such as carotid plaques), chronic obstructive pulmonary disease, acute or chronic infectious diseases, diseases of the blood system, immune system disease, patients with high uric acid hematic disease, malignant tumor and other diseases; 7. For other diseases, the life expectancy is less than 6 months; 8. Participants who are participating in another clinical trial but have not yet reached the end of the study, or who plan to participate in another clinical trial within 6 months of taking the drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine 11 - dh - TXB2 concentration;Platelet aggregation function monitoring (AA+ADP pathway);Platelet aggregation function monitoring (Col+EPT); | — |
Countries
China
Contacts
Public ContactBo Zhao
Outcome results
None listed